FOR IMMEDIATE RELEASE

CTI Redirects Efforts

Ogden, UT., Dec. 18, 2005 -- Computerized Thermal Imaging, Inc. (CTI) [OTC symbol COIB.OB] announced today it has taken a new approach to strategically revitalize its position in health care infrared imaging.  Management believes this shift has the potential to elevate CTI’s role both in the service and support of health care providers worldwide. 

Three years ago the U.S. Food and Drug Administration denied clearance for CTI’s BCS 2100 breast cancer diagnostic system.  CTI has continued to pursue a reversal of this decision.  However, the financial consequences to CTI have been difficult.  CTI has therefore made a major turn and is concentrating its current efforts on a different segment of the healthcare market. 

During the past year CTI has re-directed its marketing and sales focus to the CTI Thermal Imaging Processor (TIP) and the Photonic Stimulator products.  “Both devices have FDA clearances and we believe we are positioned to answer the call for better physiological infrared imaging technology and therapeutic treatment of a wide array of medical ailments,” stated CEO R.V. Secord.  Better known as the “find it” and “fix it” duo, these medical device leaders are effective screening and treatment modalities in worker’s compensation, physical therapy and pain management situations.   “CTI remains resolute in its firm commitment to backing and advancing the Company’s medical infrared imaging services and technologies into 2006 and beyond,” said Secord.

The Company currently plans to continue installation of its TIP and Photonic Stimulator devices and related training in several new sites beginning January 2006.  CTI intends to post additional public information releases from time to time with details as these new sites become operational.  Appropriate information will also be posted on CTI’s web site www.cti-net.com .

About Computerized Thermal Imaging, Inc. ™
Computerized Thermal Imaging Inc. (OTC symbol COIB.OB) is in business to improve the quality of life through the development and deployment of thermal imaging and associated technologies. While CTI’s infrared technology has a vast array of existing and potential applications, its primary focus is in medical and industrial application. CTI markets two FDA-cleared pain management products, a diagnostic Thermal Imaging Processor (camera) and an infrared light therapy device called the Photonic Stimulator.

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends and certainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are CTI's ability to continue as a going concern given its current financial condition, CTI's pending application before the FDA seeking pre-market approval of CTI's BCS 2100 breast imaging system, and CTI's ability to raise additional capital to fund cash requirements for future operations. In particular, careful consideration should be given to cautionary statements made in the various reports CTI has filed with the Securities and Exchange Commission. CTI undertakes no duty to update or revise such forward-looking statements.